drug persistence
Figure 5 · Panel A
Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Jean-Frederic Colombel, William J Sandborn, Stefan Schreiber, Silvio Danese, Maria Kłopocka, Jarosław Kierkuś, Roman Kulynych, Maciej Gonciarz, Artur Sołtysiak, Patryk Smoliński, Slobodan Srećković, Ekaterina Valuyskikh, Adi Lahat, Marek Horyński, Antonio Gasbarrini, Marina Osipenko, Vladimir Borzan, Maciej Kowalski, Daria Saenko, Ruslan Sardinov, Sang Joon Lee, Sunghyun Kim, Yunju Bae, Sunhee Lee, Seulgi Lee, Joon Ho Lee, Jong Min Kim, Gahee Park, Jimin Lee, Juhyun Lee, Jae Yeoul Ryu, Bruce E Sands, Stephen B Hanauer
J Crohns Colitis 19(6) jjaf060
BACKGROUND AND AIMS: In the LIBERTY phase 3 studies in Crohn's disease (CD) or ulcerative colitis (UC), maintenance CT-P13 subcutaneous (SC) 120 mg was more effective than placebo after 1 year. Here we report 2-year data from the LIBERTY open-label extensions. METHODS: Two randomized, placebo-controlled, double-blind studies evaluated the efficacy and safety of CT-P13 SC maintenance in moderate-to-severe CD or UC. Responders to CT-P13 intravenous induction were randomized at week (W) 10 to CT-P13 SC 120 mg or placebo biweekly, until W54. From W22, dose adjustment to CT-P13 SC 240 mg was permitted for loss of response. At W56, patients could enter an open-label extension, receiving CT-P13 SC 120 mg (or 240 mg if dose-adjusted), biweekly, until W102. RESULTS: The extension comprised 278/343 (81.0%) and 348/438 (79.5%) patients in the CD and UC studies, respectively. In those continuing on-study, efficacy (non-responder imputation) was well maintained in the CT-P13 SC group at W102: 63.5% (as-observed: 70.5%) and 49.0% (as-observed: 58.8%) of CD patients (N = 192) achieved clinical remission and endoscopic response, respectively; 45.1% (as-observed: 60.1%) and 41.4% (as-observed: 52.4%) of UC patients (N = 237) achieved clinical remission and endoscopic-histologic mucosal improvement, respectively. No new safety signals were identified from longer-term CT-P13 SC treatment or starting CT-P13 SC 120 mg after placebo, with similar adverse event rates for patients undergoing dose adjustment to CT-P13 SC 240 mg from CT-P13 SC 120 mg or placebo. CONCLUSION: CT-P13 SC is an effective and well-tolerated long-term maintenance treatment in moderate-to-severe CD and UC. CLINICALTRIALS.GOV IDENTIFIERS: NCT03945019 (CD) and NCT04205643 (UC).
1 个 Figure · 2 个 KM 面板
Figure 5. Kaplan–Meier plots of drug persistence (all-randomized population) in the CD study (A) and the UC study (B). Patients in the CT-P13 SC 120 mg group who received at least one administration of study drug after randomization are included in this figure. Time (weeks) to drug persistence is derived as the last study drug administration visit for patients with early discontinuation of study drug administration. Patients who completed study drug administration at W102 are considered censored at W102. Patients were considered to be receiving study drug regardless of dose adjustment. CD, Crohn’s disease; SC, subcutaneous; UC, ulcerative colitis; W, week.
这些图片未产生 KM 曲线结果,不在主页面重复展示。